Compare JHX & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JHX | VTRS |
|---|---|---|
| Founded | 1888 | 1961 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 12.0B |
| IPO Year | N/A | N/A |
| Metric | JHX | VTRS |
|---|---|---|
| Price | $19.98 | $10.94 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 6 |
| Target Price | ★ $28.60 | $11.17 |
| AVG Volume (30 Days) | 6.6M | ★ 7.9M |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 4.39% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | $4,116,899,999.00 | ★ $14,124,400,000.00 |
| Revenue This Year | $24.54 | N/A |
| Revenue Next Year | $15.32 | $1.16 |
| P/E Ratio | $59.44 | ★ N/A |
| Revenue Growth | ★ 4.60 | N/A |
| 52 Week Low | $16.46 | $6.85 |
| 52 Week High | $29.83 | $13.13 |
| Indicator | JHX | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 60.39 |
| Support Level | $19.14 | $10.67 |
| Resistance Level | $19.90 | $10.93 |
| Average True Range (ATR) | 0.57 | 0.24 |
| MACD | 0.31 | 0.01 |
| Stochastic Oscillator | 97.74 | 90.23 |
James Hardie is a manufacturer of fiber cement-based building products, selling primarily to the residential construction industry. North America is the primary geography, generating about 80% of group earnings. Here, it is the largest manufacturer of fiber cement, which is mainly used for exterior siding on houses. Following the Azek acquisition in 2025, it also produces wooden composite decking materials, siding trims, and accessories for outdoor areas including stair and deck railing. Businesses in Australia, New Zealand, and Europe, make up the rest of earnings.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.